he long development cycles in biotech are a bit of a boon in these tumultuous times, a new report from EY posits.

The Trump presidency’s threats to science funding and views on health reform, Brexit, and public scrutiny on pricing have all cast uncertainty on the capital markets in the U.S. and Europe. And research and development productivity is worrisome. The result: Revenue growth for the public biotech companies faltered last year, and net income plummeted. However, valuations have been brought back down to Earth, which encourages M&A.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.